Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sPD1-p24fc
- Development stage
- Preclinical
- Lead developer
- The University of Hong Kong
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intramuscular (with Electroporation)
01
Overview
sPD1-p24fc is a DNA vaccine encoding a fusion protein that links the soluble extracellular domain of Programmed Death-1 (sPD1) to the HIV-1 GAG p24 antigen and an Fc fragment, designed for in vivo targeting of dendritic cells (DCs) via PD-L1/PD-L2. This vaccine aims to amplify adaptive immune responses by cross-presenting the HIV-1 p24 antigen to CD8+ T cells and inducing potent, durable, polyfunctional, cytotoxic, and protective GAG-specific CD8+ T cell immunity. Its mechanism involves DC targeting to enhance vaccine efficacy, particularly important for HIV-1 infection, as p24-specific CD8+ T cells play a role in viral containment. The vaccine is delivered by electroporation of the DNA construct and has been described as uniquely immunogenic, with minimal adjuvant effect from the Fc fusion and critical dependence on the sPD1-p24 structure for immune enhancement[1][3][5][7][9].
- Other names
- sPD1-p24fcsPD-1-p24fcsPD 1-p24fc
02
Targets
HIV-1 p24-specific B and T cell receptorsCD274 (Programmed cell death protein 1 ligand 1)PDCD1LG2 (Programmed cell death 1 ligand 2)p24 (HIV-1 capsid protein p24)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on sPD1-p24fc.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sPD1-p24fc.